Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced
today that the Company has been issued European Patent No. EP0991660
for its lead immunosuppressive drug, ISA247. The patent entitled
"DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS
IMMUNOMODULATING AGENTS" is the ninth patent to be issued
internationally in this patent family. Patents relating to these
claims have issued in the following countries; Australia (No.
750245, issued July 11, 2002 and No. 774744 issued October 21,
2004), Canada (No. 2,298,572 issued April 9, 2002 and No. 2,372,639
issued November 1, 2005); New Zealand (No. 502362 issued September
6, 2001), South Korea (No. 585348, issued June 1, 2006) and the
United States (No. 6,605,593 issued August 12, 2003 and No.
6,613,739 issued September 2, 2003).
"We are pleased to add another international patent in a major
market to our portfolio," stated Dr. Randall Yatscoff, Isotechnika's
President and Chief Executive Officer. "Several additional
patentable claims for ISA247 continue to be investigated and pursued
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 has completed an extension
protocol of a Canadian Phase III human clinical trial for the
treatment of moderate to severe psoriasis and is currently involved
in a North American Phase IIb human clinical trial for the
prevention of kidney graft rejection . The Company also has an
additional immunosuppressive compound in its drug pipeline, TAFA93
which successfully completed Phase I clinical trials.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
Partnerships with Isotechnika Inc.
Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications.
On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of ISA247 and TAFA93 specifically with drug eluting devices for
the non- systemic treatment of vascular, cardiovascular, target
vessel and tissue disorders.
Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of ISA247 in patients suffering from mild to moderate
On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, ISA247 for the treatment and prophylaxis of all ophthalmic
This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.ch
For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., +1-(780)-487-1600 (246), +1-(780)-484-4105 (fax),
firstname.lastname@example.org; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., +1-(780)-487-1600 (243),
+1-(780)-487-1500 (fax), email@example.com